<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bavbek, Sevil E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Compassionate Use with CbzP Plus Prednisone for mCRPC: Interim Results</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">NP-NP</style></pages><abstract><style  face="normal" font="default" size="100%">The XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer [TROPIC; NCT00417079] trial showed that treatment with cabazitaxel (CbzP) produced statistically significant improvement in overall survival versus mitoxantrone plus prednisone in patients with metastatic, castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen (HR, 0.70; p&lt;0.0001). This article discusses interim results from a cohort compassionate-use program with CbzP plus prednisone for patients with mCRPC [EAP; NCT01254279; Bavbek SE et al. J Clin Oncol (suppl; asbtr e15112) 2012].</style></abstract><number><style face="normal" font="default" size="100%">7</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>